Welcome: Guest | Site Use Options | Register | Login |

C2N Diagnostics LLC

C2N Diagnostics LLC

Profile last edited on: 6/18/2021
4041 Forest Park Avenue
Saint Louis, MO 63108
  (314) 633-1886
  info@c2ndiagnostics.com
  www.c2ndiagnostics.com
Business Identifier: Assays to assist in neurodegenerative disease diagnosis and drug discovery
Public Profile:
Based on technology developed within the neuroscience laboratories of Washington University School of Medicine, Saint Louis, MO, LifeTech Research, Inc. of Baltimore MD co-founded C2N Diagnostics. In late January 2019, U.S. Food and Drug Administration (FDA) granted a Breakthrough Device Designation for C2N's proprietary brain amyloidosis blood test. This test will be used to screen for brain amyloid pathology in individuals being assessed for an Alzheimer's Disease diagnosis. To qualify for the FDA's Breakthrough Device Program, a medical device must provide more effective diagnosis or treatment of a life-threatening or irreversibly debilitating condition, among other criteria. This program is designed to expedite the development and review of such medical devices. The core competency of C2N Diagnostics is study of the metabolism of neurally derived biomolecules intended to catalyze important new therapeutic and diagnostic discovery efforts directed toward disorders characterized by mishandled proteins and other biomolecules within the brain. C2N Diagnostics, LLC is developing a suite of biomarker assays and tools to assist in pre-clinical drug discovery, clinical drug development, and the early detection and assessment of progression of debilitating neurodegenerative disorders. The companys first commercial tool, the SILK-Aߙ assay, relies on stable isotope labeling and tandem mass spectrometry for the precise measurement of the kinetics, or in vivo metabolism, of amyloid-beta a small peptide implicated as a key mediator of Alzheimers disease. Other products are in development to target Parkinsons disease, Huntingtons disease, schizophrenia, and amyotrophic lateral sclerosis (ALS), among others.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

WikiProfile

Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920

  support@inknowvation.com